Revenue expanded from $300.0M in Q2 2024 to $371.1M in Q3 2026 while gross margin stayed in a narrow 19.4% to 23.0% band and operating margin fluctuated between 3.7% and 9.2%, indicating uneven operating leverage despite top-line growth.
Guardian Pharmacy Services, Inc. (GRDN) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 1.46B | 1.45B | 1.23B | 1.05B | 908.91M | 792.07M | 735.96M | 698.29M | 600.37M |
| Revenue Growth % | 4.85% | 17.93% | 17.42% | 15.1% | 14.75% | 7.62% | 5.39% | 16.31% | - |
| Cost of Goods Sold | 1.13B | 1.17B | 984.04M | 837.88M | 723.04M | 630.81M | 588.96M | 554.83M | 477.33M |
| COGS % of Revenue | - | 80.53% | 80.11% | 80.09% | 79.55% | 79.64% | 80.03% | 79.46% | 79.51% |
| Gross Profit | 327.08M | 282.04M | 244.37M | 208.31M | 185.87M | 161.26M | 147M | 143.46M | 123.03M |
| Gross Margin % | 22.45% | 19.47% | 19.89% | 19.91% | 20.45% | 20.36% | 19.97% | 20.54% | 20.49% |
| Gross Profit Growth % | - | 15.42% | 17.31% | 12.08% | 15.25% | 9.7% | 2.47% | 16.6% | - |
| Operating Expenses | 227.1M | 193.13M | 307.29M | 167.36M | 133.88M | 131.12M | 114.94M | 109.36M | 97.1M |
| OpEx % of Revenue | - | 13.33% | 25.02% | 16% | 14.73% | 16.55% | 15.62% | 15.66% | 16.17% |
| Selling, General & Admin | 227.1M | 193.13M | 307.29M | 167.36M | 133.88M | 131.12M | 102.54M | 97.56M | 87.84M |
| SG&A % of Revenue | - | 13.33% | 25.02% | 16% | 14.73% | 16.55% | 13.93% | 13.97% | 14.63% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 12.4M | 11.8M | 9.26M |
| Operating Income | 99.98M | 88.91M | -62.92M | 40.95M | 51.99M | 30.15M | 32.06M | 34.1M | 25.93M |
| Operating Margin % | 6.86% | 6.14% | -5.12% | 3.91% | 5.72% | 3.81% | 4.36% | 4.88% | 4.32% |
| Operating Income Growth % | - | 241.31% | -253.67% | -21.24% | 72.44% | -5.97% | -5.97% | 31.5% | - |
| EBITDA | 123.44M | 111.25M | -43.15M | 59.18M | 68.55M | 46.68M | 49.32M | 49.95M | 39.06M |
| EBITDA Margin % | 8.47% | 7.68% | -3.51% | 5.66% | 7.54% | 5.89% | 6.7% | 7.15% | 6.51% |
| EBITDA Growth % | 52.55% | 357.83% | -172.91% | -13.67% | 46.86% | -5.36% | -1.26% | 27.86% | - |
| D&A (Non-Cash Add-back) | 23.46M | 22.34M | 19.77M | 18.23M | 16.56M | 16.53M | 17.26M | 15.85M | 13.13M |
| EBIT | 105.81M | 74.09M | -63.2M | 40.58M | 51.59M | 29.96M | 31.82M | 33.62M | 25.17M |
| Net Interest Income | -648K | -665K | -3.28M | -2.86M | -1.93M | -1.64M | -2.16M | -2.25M | -1.9M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 648K | 665K | 3.28M | 2.86M | 1.93M | 1.64M | 2.16M | 2.25M | 1.9M |
| Other Income/Expense | 5.18M | -15.49M | -3.56M | -3.23M | -2.33M | -1.82M | -2.4M | -2.73M | -2.66M |
| Pretax Income | 105.16M | 73.42M | -66.48M | 37.72M | 49.66M | 28.33M | 29.66M | 31.37M | 23.27M |
| Pretax Margin % | 7.22% | 5.07% | -5.41% | 3.61% | 5.46% | 3.58% | 4.03% | 4.49% | 3.88% |
| Income Tax | 29.11M | 24.46M | 4.56M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 27.68% | 33.32% | -6.85% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 74.77M | 49.22M | -87.29M | 23.9M | 35.42M | 16.31M | 19.94M | 21.75M | 14.68M |
| Net Margin % | 5.13% | 3.4% | -7.11% | 2.28% | 3.9% | 2.06% | 2.71% | 3.11% | 2.44% |
| Net Income Growth % | 85.81% | 156.39% | -465.19% | -32.52% | 117.12% | -18.2% | -8.29% | 48.15% | - |
| Net Income (Continuing) | 76.05M | 48.96M | -71.03M | 37.72M | 49.66M | 28.33M | 29.66M | 31.37M | 23.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 12.48M | 12.16M | 7.3M | 31.65M | 33.2M | 29.39M | 28.59M | 27.72M | 25.86M |
| EPS (Diluted) | 1.17 | 0.78 | -1.77 | 0.39 | 0.58 | 0.27 | 0.33 | 0.36 | 0.24 |
| EPS Growth % | 82.81% | 144.07% | -553.85% | -32.76% | 114.81% | -18.18% | -8.33% | 50% | - |
| EPS (Basic) | - | 0.79 | -1.77 | 0.39 | 0.58 | 0.27 | 0.33 | 0.36 | 0.24 |
| Diluted Shares Outstanding | 63.92M | 63.3M | 62.01M | 60.84M | 60.84M | 60.84M | 60.84M | 60.84M | 60.84M |
| Basic Shares Outstanding | 63.34M | 62.39M | 62.01M | 60.84M | 60.84M | 60.84M | 60.84M | 60.84M | 60.84M |
| Dividend Payout Ratio | - | - | - | 160.75% | 86.97% | 106.39% | 54.23% | 114.56% | 156.1% |
Quick answers to the most common questions about buying GRDN stock.
For fiscal year 2025, Guardian Pharmacy Services, Inc. (GRDN) reported total revenue of $1.45B. This represents a 141.3% increase compared to $600.4M in 2018.
Guardian Pharmacy Services, Inc. (GRDN) is profitable, generating $49.2M in net income for the fiscal year ending 2025 with a net profit margin of 3.4%.
Guardian Pharmacy Services, Inc. (GRDN) reported an operating income of $88.9M, resulting in an operating profit margin of 6.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Guardian Pharmacy Services, Inc. (GRDN) generated $282.0M in gross profit for the year, representing a gross profit margin of 19.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Thin margins under pricing pressure
Metrics are mathematically derived from official filings.
Top-Line Growth Losing Momentum Recently
Based on the reported quarterly income statement data, GRDN's revenue grew from $300.0M in Q2 2024 to $371.1M in Q3 2026, but year-over-year growth decelerated to -1.7% in the latest quarter after running near 17-20% through much of 2025.
The sharp swing from double-digit expansion to a modest decline suggests the growth engine may be less durable than the earlier trajectory implied. Management's attribution of revenue pressure to IRA-mandated price reductions, if accurate, would indicate that reimbursement policy rather than volume loss is driving the slowdown, though this cannot be independently confirmed from the income statement alone. Investors should monitor whether volume growth can offset policy-driven price erosion over the next several quarters.
Gross Margin Anchored Near Twenty Percent
Reported gross margin has held in a narrow 19.4% to 23.0% band across the ten quarters shown, with the most recent 23.0% reading representing the high end of that range rather than a clear structural shift.
The stability of gross margin suggests GRDN's pricing spread on pharmaceutical dispensing is structurally thin, consistent with a distribution-heavy cost base. The recent uptick to 23.0% may reflect favorable generic mix or procurement timing, but a single quarter does not establish a durable expansion. Given the thin spread, any further reimbursement compression would likely reach operating profit quickly.
Operating Income Volatile Against Revenue Gains
Operating margin fluctuated between 3.7% and 9.2% over recent quarters, with SG&A holding roughly flat near $50M to $60M while revenue expanded, indicating the operating leverage is uneven rather than consistently positive.
Because SG&A appears largely fixed in the short run, quarterly operating income swings more with gross profit timing than with revenue scale alone. The peak 9.2% operating margin in Q4 2025 coincided with lower SG&A, which suggests cost timing rather than sustained efficiency may have driven that quarter. Operating leverage has not yet demonstrated a reliable upward trajectory.
Q3 2026 Earnings Miss Versus Revenue
Reported diluted EPS of $0.29 in Q3 2026 fell short of the cited $0.41 consensus despite revenue of $371.1M, while net margin compressed to 5.0% from 6.2% the prior quarter.
The gap between operating income of $25.1M and net income of $18.7M, combined with the EPS shortfall, suggests below-the-line items or tax effects absorbed a meaningful portion of operating profit. Stock-based compensation of $2.7M is modest relative to earnings and does not appear to be the primary driver. The divergence between revenue performance and earnings warrants investigation into the components of non-operating expense.
Earnings Base Vulnerable to Reimbursement Cuts
With a 6.8% operating margin and 5.0% net margin, GRDN's profit cushion is narrow, so modest reimbursement reductions or a further SG&A step-up could erase a large share of earnings based on reported figures.
The bull case relies on the company's low leverage and strong return on equity of 26.8%, but ROE is elevated relative to thin margins, which suggests returns are being amplified by a small equity base rather than by superior unit economics. Short-seller scrutiny would likely focus on the sequential revenue decline and the EPS miss as early signs of margin pressure. Investors should monitor whether the company can sustain profitability if IRA-related price declines persist.